Bio News
Researchers at Memorial Sloan Kettering Cancer Center (MSK) in the United States found that a generative AI-designed binding protein outperformed existing treatments against BCMA, a target in multiple myeloma.
The researchers used two AI tools to generate approximately 1 million candidate binding proteins and then narrowed them to 100 to 200.
The binding protein completely suppressed tumor growth in a mouse model.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
